Today: 16 May 2026
Browse Category

LSE:JD. 9 December 2025 - 22 April 2026

FTSE 100 Today: Why London Stocks Are Stuck Near 10,500 as Inflation Bites

FTSE 100 Today: Why London Stocks Are Stuck Near 10,500 as Inflation Bites

UK inflation rose to 3.3% in March, driven by higher motor fuel prices, the Office for National Statistics said Wednesday. The FTSE 100 hovered near 10,500, down 0.04%, as losses in Reckitt and JD Sports offset gains in miners and BP. Reckitt fell 5% after missing sales forecasts and warning on margins. Investors weighed whether the inflation jump could prompt a tougher Bank of England stance.
22 April 2026
·········
UK Stock Market Top Losers Today (9 December 2025): BAT Leads FTSE 100 Fallers as Unilever Hangover Lingers

UK Stock Market Top Losers Today (9 December 2025): BAT Leads FTSE 100 Fallers as Unilever Hangover Lingers

The FTSE 100 closed down 0.1% at about 9,640 on Tuesday, its lowest in two weeks, as investors awaited central bank decisions. British American Tobacco fell 3.5–4.5% after warning of slower growth in heated-tobacco and vaping. UK consumer data showed November card spending down 1.1% year-on-year, the steepest drop since early 2021. Retail sales growth remained weak despite Black Friday.
9 December 2025
···········

Stock Market Today

  • W. R. Berkley (WRB) Shows 45.9% Undervaluation Despite Recent Price Stability
    May 15, 2026, 7:55 PM EDT. W. R. Berkley (WRB) stock has shown limited movement recently with a 1.2% gain over 7 days and a 4.2% decline year-to-date. Analysts use valuation methods like Excess Returns, which estimates intrinsic value by calculating profits above shareholder required returns. With an intrinsic value estimate of $122.79 against a current price near $66.45, the stock appears 45.9% undervalued. The insurer's steady underwriting profile and capital discipline contrast with sector concerns on insurance pricing and interest rate sensitivity. WRB currently scores 2 out of 6 on valuation metrics, highlighting potential but raising caution.

Latest articles

Accuray inks 10-year cancer tech agreement, shares in focus

Accuray inks 10-year cancer tech agreement, shares in focus

16 May 2026
Accuray and the University of Wisconsin School of Medicine and Public Health signed a 10-year research agreement focused on Accuray’s Stellar adaptive radiotherapy platform. The announcement came after market close, with Accuray shares ending down 5.2% at $0.27. The deal follows Accuray’s recent withdrawal of fiscal 2026 guidance and ongoing financial pressures.
Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

16 May 2026
Origin Materials asked shareholders to approve a plan to liquidate and dissolve the company, estimating an initial payout of $0.61 to $3.54 per share depending on asset sales and claims. Shares rose 15% to $1.43 after the filing. The company reported a 91% drop in first-quarter revenue and warned it may not survive without the wind-down. Origin cut 59% of its workforce and CEO John Bissell stepped down May 1.
NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

16 May 2026
NextNRG reported first-quarter revenue of $21.1 million, up 29% from a year earlier, but its net loss widened to $10.8 million. Cash fell to $208,048 at quarter-end, and management warned it needs immediate capital to continue operations. Shares closed at $0.2804 on Nasdaq, down nearly 6%. Total liabilities reached $34.3 million, with a stockholders’ deficit of $22 million.
HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

16 May 2026
HCW Biologics shares jumped 262% to $1.22 Friday after the company posted a $3.47 million first-quarter profit, driven by a $6.5 million licensing deal with Beijing Trimmune Biotech. The company faces a possible Nasdaq delisting and will ask shareholders to approve a reverse stock split on June 15. HCW plans to report early Phase 1 data for its alopecia drug in the first half of 2026.
Go toTop